News
Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...
Verona Pharma’s flagship drug last year became the first new maintenance treatment for chronic obstructive pulmonary disease ...
The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make ...
Merck will buy UK-based Verona Pharma for about $10 billion, the companies said on Wednesday, strengthening the U.S. firm's ...
Verona Pharma shares jumped in premarket trading Wednesday after the Financial Times reported that Merck & Co. is nearing a $10 billion deal to buy the U.K. drugmaker.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results